NeuraWorx Medical Technology, Inc. is one of those companies that makes you stop scrolling, not because it’s loud, but because the science hums. Founded in 2021 in Excelsior, MN, this clinical-stage neurotech company is chasing a part of brain health most people forgot to ask about: cerebrovascular and glymphatic function. Translation for the real world: how the brain moves blood, clears waste, and keeps firing when time, trauma, or disease start stealing margin.
The Cerebrovascular Pacing System™ didn’t come out of a pitch deck brainstorm or a late-night Slack thread. This platform was born inside the University of Wisconsin–Madison and Mayo Clinic, shaped by DARPA’s Targeted Neuroplasticity Training Program and the NIH SPARC, BRAIN, and HEAL programs. That’s federally funded, peer-reviewed science with a long memory, now licensed through Wisconsin Alumni Research Foundation and pushed toward patients with intent, not theatrics.
Chris Minar brings 32+ years of medical device scar tissue to the CEO role, with 40+ devices developed or commercialized across robotics, neuromodulation, and cardiovascular systems. Dr. Kip Ludwig adds academic and federal gravity as Associate Professor at University of Wisconsin–Madison, Co-Director of the Wisconsin Institute for Translational Neuroengineering, and former NIH Program Director leading the BRAIN Initiative and SPARC. Dr. Justin Williams anchors the science as Peter Tong Department Chair and Vilas Distinguished Achievement Professor, a pioneer in neural interfaces who understands neurons and narratives. Tamara Bratland rounds out the founding team with commercialization instincts forged at Medtronic, Abiomed, and Honeywell, experience that knows how to turn science into adoption.
The oversubscribed Seed round announced December 18, 2025 says plenty without flashing numbers. Nexus NeuroTech Ventures led, joined by Foothill Ventures, Verge HealthTech Fund, Wisconsin Alumni Research Foundation, and returning support from Corundum Neuroscience. Oversubscribed is investor shorthand for disciplined ambition meeting real demand, especially in neurotech where hype usually outruns evidence.
NeuraWorx Medical Technology, Inc. is advancing a wearable neurostimulator designed to enhance cerebral artery pulsation and cerebrospinal fluid flow, targeting TBI, Alzheimers, Parkinsons, ALS, epilepsy, and prevention for military personnel and athletes. The clinical feasibility study underway with Corundum Neuroscience is the proving ground, not the victory lap.
This raise is about scaling the right team, tightening the clinical and regulatory spine, and moving fast without breaking what matters. Neurodegeneration is a long game. NeuraWorx is playing it with patience, precision, and a quiet confidence that when the brain gets the right rhythm, it remembers how to take care of itself.
Startups Startup Funding Venture Capital Seed Round Med Device NeuroTech Brain Health Healthcare Health Tech Technology Innovation Tech Ecosystem Startup Ecosystem Hiring Tech Hiring DCTalks
